RxDoctor Payments Data

William McCrory, MD

Pulmonary Disease · Huntsville, ALNPI 1023070323

Payments from drug & device makers

$5,324in general payments, 2019–2025

Across 299 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$836
  • Regeneron Healthcare Solutions, Inc.$534
  • Insmed, Inc.$500
  • Genentech USA, Inc.$282
  • Amgen$252
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$5,01794%
  • Education$3076%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,324 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$551,453
Medicare patients
879
Services billed
11,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter562$564,404
OfevNintedanib Esylate11$196,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol151$175,727
Spiriva RespimatTiotropium Bromide160$133,378
Stiolto RespimatTiotropium Br/Olodaterol Hcl144$99,017
Breo ElliptaFluticasone/Vilanterol153$97,098
XolairOmalizumab12$67,405
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr105$64,614
Advair HfaFluticasone Propion/Salmeterol113$63,067
SymbicortBudesonide/Formoterol Fumarate104$50,865
Combivent RespimatIpratropium/Albuterol Sulfate51$40,068
Fluticasone-SalmeterolFluticasone Propion/Salmeterol123$34,683
Albuterol Sulfate HfaAlbuterol Sulfate757$34,314
Incruse ElliptaUmeclidinium Bromide67$34,212
DuleraMometasone/Formoterol50$28,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,731$769,170906 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$68$468,892366 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler$836$243,624286 claims
MerckDulera$50$28,01850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →